Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals;however,the prognosis remains poor.The BCMA antigen is highly expressed in myeloma cells,thus representing a ta...Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals;however,the prognosis remains poor.The BCMA antigen is highly expressed in myeloma cells,thus representing a target for novel therapies.Several agents that target BCMA through different mechanisms,including bispecific T cell engagers drug conjugated to antibody and CAR-T cells,are now available or under development.Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy.This review will discuss the recent development of anti-BCMA targeted treatments in myeloma,with a special focus on currently available agents.展开更多
文摘Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals;however,the prognosis remains poor.The BCMA antigen is highly expressed in myeloma cells,thus representing a target for novel therapies.Several agents that target BCMA through different mechanisms,including bispecific T cell engagers drug conjugated to antibody and CAR-T cells,are now available or under development.Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy.This review will discuss the recent development of anti-BCMA targeted treatments in myeloma,with a special focus on currently available agents.
